Where can researchers source third-party tested BPC-157?

Midwest Peptide supplies research-grade BPC-157 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

BPC-157 Cytoprotection Research | Midwest Peptide

GHK-Cu Skin Aging Research: Photoaging and SenescencePrev|BPC-157 Bone Healing Research: Fracture Animal ModelsNext

BPC-157 Cytoprotection Research: Organ Injury Studies

BPC-157 · Published April 24, 2026 · Updated May 18, 2026 · 10 min read

Quick Answer

BPC-157 cytoprotection research investigates how this pentadecapeptide protects multiple organ systems in rodent injury models, including liver, kidney, heart, and pancreas. Studies examine ischemic injury, toxin-induced damage, oxidative stress markers, and tissue-level histology across standardized organ injury protocols. For research use only, not for human consumption.

BPC-157 Cytoprotection Research: Organ Injury Studies

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Cytoprotection as a Research Concept
Hepatoprotection Research
Nephroprotection Research
Cardioprotection Research
Pancreatic Protection Research
Neuroprotection in Organ Injury Contexts
The Nitric Oxide System as a Unifying Mechanism
Gastric Cytoprotection: The Original Context
Research Design for Multi Organ Studies
Research Peptide Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

BPC-157 cytoprotection research addresses the broad spectrum of organ protective effects that have been documented in the preclinical literature beyond the specific tissue repair endpoints covered elsewhere in the BPC-157 research cluster. The "body protection compound" naming convention reflects the original research interest in the peptide as a general protective factor, and the cytoprotection literature validates this characterization across multiple organ systems in rodent injury models.

Frequently Asked Questions

What is BPC-157 in research contexts?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective sequence found in human gastric juice. It is studied in preclinical rodent models for its effects on tissue repair, vascular signaling, and cytoprotection.

Which organs are studied in BPC-157 cytoprotection research?

Published rodent studies cover liver injury (hepatotoxin exposure, ischemia-reperfusion), kidney injury models, cardiac ischemia, and pancreatic injury, alongside the well-documented gastrointestinal protection literature.

What endpoints are measured in BPC-157 organ protection studies?

Histological injury scoring, serum biomarkers of organ damage (ALT, AST, creatinine, troponin), oxidative stress markers, and tissue cytokine profiles are the most commonly reported endpoints in these models.

Is BPC-157 approved for human use?

No. BPC-157 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

Pentadecapeptide: A peptide chain composed of 15 amino acid residues linked by peptide bonds.
Cytoprotection: The biological process by which cells are protected from injury caused by chemical, ischemic, or oxidative insults.
Angiogenesis: The formation of new blood vessels from pre-existing vasculature, central to tissue repair.
VEGF: Vascular Endothelial Growth Factor, a signaling glycoprotein that stimulates new blood vessel formation.
Nitric Oxide (NO): A short-lived gaseous signaling molecule that triggers vasodilation and supports endothelial function.
Hepatotoxin: A chemical agent that causes liver damage, often used to induce hepatic injury models in research.
Ischemia-Reperfusion: Tissue injury caused by restoration of blood flow following a period of ischemia, driven largely by oxidative stress.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. BPC-157 is intended exclusively for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

Cytoprotection as a Research Concept

Cytoprotection refers to the capacity of a compound to protect cells and tissues from injury, toxicity, or pathological insult. The concept was originally developed in the gastric physiology literature to describe factors that protect the gastric mucosa from acid and enzymatic damage, and it has since been extended to describe protective effects across many organ systems. The historical connection to gastric protection is relevant to BPC-157 because the peptide was originally identified from gastric juice protective sequences as documented in the BPC-157 origins article.

The cytoprotection research on BPC-157 extends well beyond the gut. Published rodent studies document protective effects in the liver, the pancreas, the kidney, the heart, and the brain in response to various injury models. The common mechanistic thread across these diverse tissue contexts includes modulation of nitric oxide signaling, vascular protection through the angiogenic pathway, anti inflammatory effects, and stabilization of cellular stress responses. The Nature subject hub on cytoprotection and the ScienceDirect cytoprotection topic page archive the broader research framework.

Hepatoprotection Research

Liver injury models represent one of the most extensively studied organ protection contexts for BPC-157. Published research has used multiple hepatotoxicity models including alcohol induced liver injury, carbon tetrachloride induced fibrosis, acetaminophen overdose models, and bile duct ligation models. Each model produces a different pattern of liver injury, and BPC-157 has been examined in each.

The findings across these models document reductions in hepatocyte necrosis markers including alanine aminotransferase and aspartate aminotransferase release into the circulation. Histological assessment shows preserved hepatic architecture with reduced inflammatory infiltration and reduced fibrosis in the treated groups. The magnitude of protection depends on the severity of the injury model and on the timing of BPC-157 administration relative to the injury.

The mechanisms implicated in hepatoprotection overlap with the mechanisms documented in the broader BPC-157 literature. Preservation of hepatic microcirculation through the angiogenic and nitric oxide pathway effects maintains oxygen and nutrient delivery to the injured tissue. Anti inflammatory modulation reduces the secondary injury from excessive immune cell activation. Stabilization of cellular stress responses including heat shock protein expression and endoplasmic reticulum stress markers supports hepatocyte survival under toxic challenge.

The hepatoprotection research connects to the broader liver research documented in the glutathione liver article in the glutathione cluster and to the metabolic liver research documented in the GLP-2 TZ hepatic article in the tirzepatide cluster. The different compounds approach liver biology through different pathways, and the combined research landscape provides a multifaceted view of hepatic protection and repair.

The Wiley Online Library hepatology collection archives primary research on hepatoprotection mechanisms.

Nephroprotection Research

Kidney injury models have been used to examine BPC-157 protective effects in the renal compartment. Published research includes ischemia reperfusion injury models, nephrotoxic injury models using agents such as cisplatin and gentamicin, and obstructive nephropathy models. The kidney is particularly vulnerable to ischemic and toxic injury because of its high metabolic demand and its exposure to concentrated metabolites and drugs in the tubular fluid.

Published BPC-157 nephroprotection data documents reductions in serum creatinine and blood urea nitrogen, which are functional markers of renal injury. Histological assessment shows preserved tubular architecture, reduced tubular necrosis, and reduced inflammatory infiltration. Molecular markers of oxidative damage including malondialdehyde and protein carbonyls are reduced in the treated groups.

The renal microcirculation is particularly sensitive to ischemic injury, and the vascular protective effects of BPC-157 documented in the angiogenesis literature are likely relevant to the nephroprotective findings. The nitric oxide pathway modulation documented in the BPC-157 angiogenesis article would be expected to support renal endothelial function and maintain glomerular and tubular perfusion during and after injury.

Cardioprotection Research

Cardiac injury models have generated additional BPC-157 cytoprotection data. Published research includes coronary artery ligation models of myocardial infarction, doxorubicin induced cardiotoxicity models, and arrhythmia models using various proarrhythmic agents. The cardiac research adds a contractile tissue context to the BPC-157 repair profile alongside the skeletal muscle data documented in the muscle repair article.

The myocardial infarction data documents reduced infarct size in BPC-157 treated animals compared to vehicle controls, with the protective effect associated with preserved microvascular perfusion in the peri infarct zone. The cardiotoxicity data documents preserved contractile function and reduced histological damage under doxorubicin challenge. The arrhythmia data documents anti arrhythmic effects in several proarrhythmic models.

The cardiac findings connect to the cardiovascular research documented in the VIP cardiovascular article through shared vascular biology, although VIP and BPC-157 act through different receptor systems. The ScienceDirect cardioprotection topic page and the Cell Press journal Cell Reports Medicine archive primary research on cardiac protection mechanisms.

Pancreatic Protection Research

Acute pancreatitis models have been used to study BPC-157 protective effects on the exocrine pancreas. Published research uses cerulein induced pancreatitis, which produces a reproducible inflammatory injury to the pancreatic acinar cells. BPC-157 administration in these models documents reduced pancreatic edema, reduced inflammatory cell infiltration, reduced necrosis, and lower circulating amylase and lipase concentrations.

The pancreatic research connects the gastric protection origins of BPC-157 to a related digestive organ. The stomach and the pancreas share aspects of their physiology including exocrine secretion and vulnerability to self digestion. The protective mechanisms that were originally identified in gastric juice and documented in the origins article extend to the pancreatic compartment through analogous biology.

Neuroprotection in Organ Injury Contexts

Several of the organ injury models used in BPC-157 cytoprotection research include central nervous system endpoints that document neuroprotective effects in the context of systemic organ injury. Hepatic encephalopathy associated with severe liver injury, uremic encephalopathy associated with renal failure, and septic encephalopathy associated with systemic inflammatory models all produce central nervous system dysfunction that can be assessed through behavioral endpoints and through histological and molecular analysis of brain tissue.

Published BPC-157 research in these multi organ injury models documents preservation of central nervous system function alongside the organ specific protective effects. The neuroprotective component may reflect direct effects of BPC-157 on neural tissue or indirect effects through preservation of the injured organ function that reduces the secondary neurological insult. Both mechanisms likely contribute.

The neuroprotection findings in organ injury contexts complement the direct neuroscience research documented in other peptide clusters including the Semax ischemia research, the Selank GABA research, and the DSIP neuroprotection research.

The Nitric Oxide System as a Unifying Mechanism

The nitric oxide system emerges as a unifying mechanistic thread across the various organ protection contexts. In the liver, nitric oxide signaling supports hepatic microcirculation and modulates the inflammatory response. In the kidney, nitric oxide supports glomerular and tubular perfusion. In the heart, nitric oxide supports coronary vasodilation and has direct cardiomyocyte protective effects. In the pancreas, nitric oxide supports the microvascular perfusion that is critical for tissue survival.

The documented effects of BPC-157 on nitric oxide synthase expression and activity, covered in detail in the angiogenesis article, provide a mechanistic framework for understanding how a single peptide can produce protective effects across multiple organ systems. The nitric oxide system is a shared downstream target that operates in every vascularized tissue, and modulation of this system would be expected to produce effects wherever the tissue is under ischemic, toxic, or inflammatory stress.

The Frontiers in Pharmacology open access journal and the Wiley Online Library nitric oxide research collection both archive primary research on the integrated role of nitric oxide in organ protection.

Gastric Cytoprotection: The Original Context

The cytoprotection concept began with gastric protection, and BPC-157 research in gastric injury models remains part of the active literature. The gut barrier article covers the intestinal research in detail. The gastric specific research adds NSAID induced gastric lesion models, ethanol induced gastric injury models, and stress ulcer models that test the peptide's effects on the gastric mucosa specifically.

The gastric research findings are consistent with the broader cytoprotection profile. BPC-157 reduces gastric lesion formation, accelerates gastric mucosal healing, and modulates the gastric microcirculation in these models. The gastric context is the foundation of the cytoprotection concept for this peptide, and the extension into liver, kidney, heart, pancreas, and other organs represents the generalization of this original observation.

Research Design for Multi Organ Studies

Research design for cytoprotection studies should consider whether the question is about a specific organ or about the general protective capacity. Single organ studies provide the deepest data on the specific tissue but may miss interactions with other organ systems. Multi organ studies that measure endpoints across several tissues provide a broader view but require larger sample sizes and more complex analytical plans.

The systemic delivery routes documented in the delivery article are appropriate for studies that want to assess protection across multiple organs because the peptide distributes systemically through the circulation. Local delivery is appropriate for studies that want to maximize the protective effect in a specific organ.

The timing of administration relative to the injury is critical in cytoprotection research. Pre treatment designs test prevention. Post treatment designs test rescue. Both are informative, but they answer different questions. Studies that include both timing conditions provide the most complete picture of the protective capacity.

Research Peptide Referenced

BPC-157 10mg, research grade pentadecapeptide, third party COA

For complete sourcing details see the BPC-157 sourcing guide.

Within the BPC-157 cluster:

Related clusters:

Not for human consumption. Research use only.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

DSIP, 99%+ purity, COA included
Glutathione 1500mg, 99%+ purity, COA included
VIP 10mg, 99%+ purity, COA included
Selank 10mg, 99%+ purity, COA included
Semax 10mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

BPC-157 Cytoprotection Research: Organ Injury Studies

Frequently Asked Questions

What is BPC-157 in research contexts?

Which organs are studied in BPC-157 cytoprotection research?

What endpoints are measured in BPC-157 organ protection studies?

Is BPC-157 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Cytoprotection as a Research Concept

Hepatoprotection Research

Nephroprotection Research

Cardioprotection Research

Pancreatic Protection Research

Neuroprotection in Organ Injury Contexts

The Nitric Oxide System as a Unifying Mechanism

Gastric Cytoprotection: The Original Context

Research Design for Multi Organ Studies

Research Peptide Referenced

Ready to Start Your Research?

Where can researchers source third-party tested BPC-157?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

BPC-157 Cytoprotection Research: Organ Injury Studies

Frequently Asked Questions

What is BPC-157 in research contexts?

Which organs are studied in BPC-157 cytoprotection research?

What endpoints are measured in BPC-157 organ protection studies?

Is BPC-157 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Cytoprotection as a Research Concept

Hepatoprotection Research

Nephroprotection Research

Cardioprotection Research

Pancreatic Protection Research

Neuroprotection in Organ Injury Contexts

The Nitric Oxide System as a Unifying Mechanism

Gastric Cytoprotection: The Original Context

Research Design for Multi Organ Studies

Research Peptide Referenced

Related Research Reading

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested BPC-157?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?